News

Back

TheraVet broadens its bone subtitutes portfolio with an innovative line of biological bone grafts

February 7th 2022

BSCB Dev

TheraVet, a pioneering company in the management of osteoarticular diseases in pets, announces today an exclusive partnership expanding TheraVet’s bone substitutes portfolio with a new and complementary biological bone graft product line, “BIOCERA-VET® SmartGraft”.

Read Pdf